Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT04248465 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- March 30, 2020
- Completion date
- October 17, 2021
- Enrollment
- 382 (actual)
- Sites
- 95
Conditions
As the registry lists them; a condition with its own page is linked.